Literature DB >> 24382282

Analysis of clinicopathologic correlations in Iranian patients with lupus nephritis.

Zhaleh Shariati-Sarabi1, Amin Ranjbar, Seyed M Monzavi, Habibollah Esmaily, Mehdi Farzadnia, Abbas A Zeraati.   

Abstract

OBJECTIVE: To determine clinical features of different histopathological presentations in patients with lupus nephritis (LN).
METHODS: Clinical and pathological features of 71 biopsy-proven LN patients were analyzed in a cross-sectional study during 2005-2011.
RESULTS: Sixty-five women (91.5%) and six men (8.5%) were studied. The mean Activity Index (AI) and Chronicity Index (CI) were 6.2 ± 3.1 and 1.7 ± 1.5, respectively. The most common histopathologic presentation of kidneys was class IV (52.1%). Patients with more advanced International Society of Nephrology and the Renal Pathology Society (ISN/RPS) classes, had longer disease duration (P = 0.007), higher levels of blood urea nitrogen (P = 0.004) and serum creatinine (P = 0.035). The most frequent active lesion seen in renal biopsies was endocapillary hypercellularity (83.1%) while glomerular sclerosis was the most common chronic lesion (52.1%). Patients with chronic lesions, including glomerular sclerosis (P = 0.032), fibrous crescent (P = 0.001), interstitial fibrosis (P = 0.025) and tubular atrophy (P = 0.049) had higher serum creatinine levels. Hypertension was mainly seen in patients who had interstitial fibrosis and tubular atrophy (P = 0.026, 0.002 respectively). Moreover, subjects with renal failure had been more frequently involved with fibrinoid necrosis/karyorrhexis (P = 0.003), interstitial inflammation (P = 0.009), fibrous crescents (P = 0.041), tubular atrophy (P = 0.008) and interstitial fibrosis (P < 0.001).
CONCLUSION: We found that both histopathologic classification (ISN/RPS criteria) and histopathologic grading (US National Institutes of Health activity and chronicity indices) correlate to some clinical manifestations of LN. Considering these correlations may help to determine the patients' clinicopathologic status, prognosis and the need to immediate treatment. Nevertheless, it is necessary to clarify the accuracy of these findings in larger-scale prospective studies.
© 2013 The Authors International Journal of Rheumatic Diseases © 2013 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  Activity Index; Chonicity Index; ISN/RPS classification; SLE; lupus nephritis

Mesh:

Substances:

Year:  2013        PMID: 24382282     DOI: 10.1111/1756-185X.12059

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  5 in total

1.  The expression of EBV-encoded LMP1 in young patients with lupus nephritis.

Authors:  Yan Ding; Xiaojie He; Wang Liao; Zhuwen Yi; Huilan Yang; Wei Xiang
Journal:  Int J Clin Exp Med       Date:  2015-04-15

2.  Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers.

Authors:  Seyed Mostafa Monzavi; Aida Alirezaei; Zhaleh Shariati-Sarabi; Jalil Tavakol Afshari; Mahmoud Mahmoudi; Banafsheh Dormanesh; Faezeh Jahandoost; Ali Reza Khoshdel; Ali Etemad Rezaie
Journal:  Inflammopharmacology       Date:  2018-07-10       Impact factor: 4.473

3.  Clinicopathological correlation in asian patients with biopsy-proven lupus nephritis.

Authors:  Bancha Satirapoj; Pamila Tasanavipas; Ouppatham Supasyndh
Journal:  Int J Nephrol       Date:  2015-03-19

4.  Clinical and laboratory predictors of distinct histopathogical features of lupus nephritis.

Authors:  Clio P Mavragani; George E Fragoulis; George Somarakis; Alexandros Drosos; Athanasios G Tzioufas; Haralampos M Moutsopoulos
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

5.  Clinicopathological correlations in lupus nephritis; a single center experience.

Authors:  Hamid Nasri; Ali Ahmadi; Azar Baradaran; Ali Momeni; Parto Nasri; Saeed Mardani; Mahmood Rafieian-Kopaei; Muhammed Mubarak
Journal:  J Nephropathol       Date:  2014-04-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.